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cyclooxygenase inhibition and evidence of 
independent gene regulation*
Numerous studies have reported altered in vitro cytokine production in various 
diseases. In the present study we used specific immunoassays to quantita te  
production of interleukin 1(3 (IL 1(3), IL l a ,  tum or necrosis factor (TNF) and IL 2  
from human peripheral blood m ononuclear cells (PBMC). The distribution of 
cell-associated and secreted cytokines was studied in PBM C of 21 individuals; in 
response to lipopolysaccharide (LPS) the proportion of cell-associated IL 1(3 
ranged from 13% to 56% , for IL l a  29% to 98% , and for T N F 2% to 17%. In a 
larger cohort of 32 subjects, the total am ount of immunoreactive cytokines 
produced in response to LPS or phytohemagglutinin was normally distributed 
within the study group. Mean production of I L l a  in response to LPS was
10.1 ng/ml and exceeded production of IL 1(3 (5.6 ng/ml) and T N F (2.2 ng/ml). 
The distribution pattern  was characterized by high intersubject variability 
extending over two orders of magnitude and the presence of high and low 
“producers”. Production of I L l a  and IL1|3 correlated (7? =  0.69). In contrast, 
production of IL 1(3 did not correlate with production of T N F  or IL2. 
Indom ethacin  present during stimulation of PBM C increased the am ount of IL 1(3 
producd and showed a high correlation (R  =  0.83) compared to cultures without 
indom ethacin .Thus, low production of IL 1(3 in certain subjects appears not to be 
due to inhibitable levels of cyclooxygenase products. In a retrospective study, 
PBM C from 12 subjects who had taken oral cyclooxygenase inhibitors during the 
preceding 7 days produced 43% more IL 1(3 than subjects who did not take these 
drugs ( p < 0 .0 5 ) .  These studies dem onstrate  that the am ount of cytokine 
synthesized by PBM C (a) is regulated independently for IL 1 ,T N F and IL 2 ;  (b) 
correlates for IL 1(3 and IL l a ;  (c) is intrinsic for low and high “producers”, and (d) 
production of IL 1(3 increases with the use of oral cyclooxygenase inhibitors.
1 Introduction
IL 1 and T N F  participate in the host’s response to acute and 
chronic injury, infection, immunologic challenge or malig­
nant disease. A  widely used m ethod to help elucidate the 
role of these cytokines in the pathogenesis of different 
diseases involves measuring cytokine production from 
stimulated blood leukocytes. A ltered production of IL 1 in 
vitro has been reported in several diseases [1]. Increased 
production of T N F  in vitro occurs in some cancer patients 
[2]. Reduced IL 2  production in vitro has been observed in 
patients with A ID S [3], some forms of cancer [4], rheum a­
toid arthritis [5], SLE [6] and type I diabetes mellitus
[7].
Because of these reports on altered levels of in vitro 
production of IL l ,T N F o r  IL 2  in disease, the present study
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was designed to define normal ranges and the distribution 
patterns of production of those cytokines in vitro in a cohort 
of normal volunteers. The cytokines were quantified by 
specific R IA  or ELISA to avoid confounding factors 
introduced by the use of bioassays. For the different 
cytokines we found a varying degree of correlation within 
the study group, indicating independent regulation of their 
production. Furtherm ore , we dem onstrated  an enhancing 
effect of either in vivo or in vitro cyclooxygenase inhibition 
of cytokine production.
2 Materials and methods
2.1 Study population
The study was approved by the H um an  Investigation 
Review Committee of the New England Medical Center 
Hospitals. Healthy volunteers were recruited from labora­
tory and hospital personnel. Each volunteer completed a 
standardized questionnaire on medical history, medication, 
smoking habits and diet. Blood was obtained during the 
morning hours.
2.2 In vitro PBMC stimulation
Twenty milliliters of venous blood was drawn into heparin- 
ized (20 U/ml) syringes. The PBM C fraction was obtained
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by centrifugation of diluted blood (1  part blood to 2 parts 
pyrogen-free normal saline) over Ficoll-Hypaque (Ficoll 
Type 400; Sigma, St. Louis, M O ; and Hypaque-M , 90%; 
W inthrop-Breon Lab .,  New York, NY) which was diluted 
in ultrafiltered water. PBM C were washed twice in 0.15 M 
NaCl and slides were prepared by cytocentrifugation. O ne 
hundred cell differential counts were performed in a blind 
fashion on coded slides after staining with Wright's stain. In 
addition, some PBM C preparations were stained for non­
specific esterase (Sigma) and 200 cells were counted. 
RPM I 1640 culture medium (W hittaker M. A. Bioproducts, 
Walkersville, M D ), supplem ented with 2 m M  L-glutamine, 
100 U/ml penicillin and 100 |ig/ml streptomycin, was ultra­
filtered (hollow fiber filter U2000; G am bro, Hechingen, 
F R G ) in o rder  to remove LPS and o ther  microbial products 
as previously described [8] .The Ficoll-Hypaque and RPMI 
media were LPS negative by the Limulus amebocyte lysate 
assay with a detection limit of 20 pg/ml (Associates of Cape 
Cod, Woods Hole, M A). PBM C were suspended at 
5 x  106/ml in RPM I with 2% heat-inactivated human serum 
from a single AB donor, and 100 |il was aliquoted in each 
well of 96-well flat-bottom microtiter plates. A n equal 
volume of either RPM I (control) or RPM I containing 
various stimulants was then added. The cells were stimu­
lated with LPS (from E. coli 0 5 5  :B5; Sigma) or with 
P H A -P  (Difco, Detroit,  MI) at indicated concentrations. 
LPS concentrations ranging between 0.5 and 10 ng/ml were 
chosen because they more closely approximate clinical 
situations than concentrations up to 50 ug/ml used in some 
o ther  studies. Stimulus aliquots were stored at 1 ¡ig/ml 
stock concentration for LPS and at 600 (.ig/ml for P H A , and 
were diluted in RPM I immediately before use. All stimuli 
were added to duplicate wells. In part of the study cells were 
incubated with or without 1 j-ig/ml indomethacin. Crystal­
line indomethacin (Sigma) was diluted in 95% ethanol at 
100 mg/ml. This stock solution was diluted with RPM I to 
2 mg/ml and stored in aliquots at —70°C.The aliquots were 
diluted 1000-fold immediately before use.
A fter  24 h at 37 °C in 5% C O 2, SN in the wells were 
replaced by medium for some of the subjects. The micro­
titer plates containing the cells were frozen at — 70 °C. A t 
the end of each study all plates were simultaneously thawed 
and exposed to two more freeze-thaw cycles to lyse the 
cells. The contents of duplicate wells, consisting of cell 
lysates and SN, were pooled, spun at 13 000 x  g for 1 min 
and the SN was refrozen at — 70 °C. Approximately  one 
month later, the samples were diluted in 0.01 m  phosphate- 
buffered saline containing 0.25% BSA and 0.05% sodium 
azide (BSA buffer) for cytokine assays. Dilutions of the cell 
SN or lysates were adjusted to obtain measurements in the 
sensitive range of the standard curves of each cytokine 
assay.
2.3 Cytokine determinations
IL 1(3 [9, 10], I L l a  and T N F  [12] were determ ined  by 
specific R IA  as previously described. These R IA  employ 
polyclonal antisera raised in rabbits against human recom ­
binant IL 1(3, IL l a  or TNF. Briefly, samples were incubated 
with specific antibody overnight, and radioiodinated cyto­
kine tracer was added and allowed to equilibrate during 
ano ther  overnight incubation. Finally, bound radioactivity 
was precipitated by sheep anti-rabbit IgG antiserum and
the antibody-antigen complexes were precipitated by cen­
trifugation. Radioactivity in the pellet was determ ined in a 
gamma counter and expressed as percent binding of a zero 
standard. Cytokine concentration was read from a standard 
curve obtained with serial dilutions of known standards. 
Recombinant cytokines for iodination and standard curves 
were kindly provided by Dr. Alan Shaw, Glaxo Institute of 
Molecular Biology, Geneva, Switzerland. IL 2  was de te r­
mined by ELISA (Genzyme Corp .,  Boston, M A). Statis­
tical analysis was performed using Stat-View software 
(Abacus Concepts Inc., Calabasas, CA) on a Macintosh SE 
com puter (Apple C om puter  Inc, Cupertino , CA) and on a 
Clinfo software system (Bolt, Beranek and Newman, 
Cambridge, M A).
3 Results
3.1 Cell-associated vs. secreted cytokine
Cytokine levels were quantified separately in the cell- 
associated and secreted compartments. PBM C from 21 
donors were stimulated with 10 ng/ml of LPS for 24 h. SN 
was withdrawn and replaced with medium. Cells in the 
medium were lysed by three freeze-thaw cycles. Cytokine 
concentrations were determ ined by R IA  in the SN (se­
creted com partm ent)  and in the lysate (cell-associated 
com partm ent)  (Fig. 1). I L l a  remains mostly cell asso­
ciated (median 72% ), slightly more IL 1(3 is secreted than 
remains cell associated (median 39%) and very little T N F  
remains cell associated (median 10%). These results con­
firm previous studies on the distribution of cytokines 
between the cell-associated and the secreted com partm ents  
[13, 14]. Furtherm ore , for a given cytokine there is wide 
interindividual variation in the am ount of cell-associated 
cytokine, ranging from 13% to 56% for IL 1(3, from 29% to 
98% for IL l a  and from 2% to 17% for TNF.
Because of the considerable proportion of cell-associated 
cytokine, the differences in this proportion for different 
cytokines and the wide interindividual variation, de term i­
nation of the combined cell-associated and secreted com-
100  -
CD
c  _____ _
^  CD
O .E
80-
o >o 60-" O0) — CC03
•—  Oo £
o  rw *-(/) o 
<
CD
O
40-
2 0 -
0
0
e
g
8
g T0
1
0
00 0
IL 1B IL 1 a TNF
Figure 1. Relative proportion of cell-associated vs. total cytokine 
production. PBMC from 21 subjects were stimulated with 10 ng/ml 
of LPS. Cytokine concentrations were determined by RIA in the 
SN (secreted) and the lysate (cell associated). Horizontal bars 
indicate the mean proportion of cell-associated compartment for 
each cytokine. IL l a  concentrations were available for 18 of the 21 
subjects.
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partm ent was necessary in order to compare the am ount of 
cytokine synthesized between IL 1(3, IL l a  and TNF.
3.2 Normal distribution of cytokine production
O f the group of 44 volunteers, 32 of the subjects indicated 
that they had not taken any medication for at least 1 week, 
whereas 12  volunteers had taken cyclooxygenase inhibitors 
during the past week (5 subjects Aspirin, 5 subjects 
Ibuprofen, 2 subjects Naproxen). Age and sex distribution 
of the two cohorts are summarized in Table 1. The mean 
response to 0.5 ng/ml of LPS was 10.1 ng/ml of I L l a ,  
5.6 ng/ml of IL 1(3 and 2.2 ng/ml of T N F (Table 2) for 
PBM C from the study cohort without medication. Previous 
studies have shown that 0.5 ng/ml of LPS does not stimu­
late IL 2  production from PBM C in vitro. Therefore , we
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Figure2. Interindividual distribution of cytokine production. 
PB M C  from 32 subjects were stimulated with 0.5 ng/ml LPS for 
induction of IL 1(3, I L l a  and TNF, and with 30 ¡.ig/ml P H A  for 
induction of IL 2.Total (cell-associated plus secreted) cytokine was 
de te rm ined  by R IA  or ELISA .
used P H A  as a stimulus for IL 2  production. In vitro 
production of IL 2  in response to 30 [ig/ml of P H A  averaged 
9.4 ng/ml. The distribution of in vitro cytokine production 
in this study group is depicted in Fig. 2 .There  was a normal 
distribution for all four cytokines as calculated by the 
Wilk-Shapiro test. The largest SD (6.9 ng/ml) was seen for 
IL 2  production, indicating high intersubject variability.
Table 1. Characteristics of study cohort
3.3 Covariation of cytokines
Fig. 2 shows that cytokine production from the cells of 
different donors vary up to two orders of magnitude. 
Correlation analysis was next performed to determine 
w hether  an individual with high production of one cytokine 
also exhibits high production of o ther  cytokines in response 
to a given stimulus. Production of IL 1 and T N F  using LPS 
as a stimulus was compared. Fig. 3A depicts the production 
of T N F  vs. the production of IL 1(3. Each square represents 
the data  obtained from a single individual’s PBM C culture 
sitmulated with 0.5 ng/ml of LPS. The quadrants of the 
graph, defined by the median production of each cytokine, 
distribute the subjects according to their cytokine response: 
low T N F  and low IL 1(3 producers, high T N F and high IL 1(3 
producers, and the two groups with mixed responses. The 
subjects are equally distributed in the four quadrants, 
indicating independent variation of production. This is 
reflected by a low correlation coefficient of R = 0.18. The 
correlation of IL l a  to T N F  production is also low 
(R  =  0.44; data not shown).
In contrast, there is a high correlation of IL 1(3 production 
with production of IL l a .  The majority of subjects fall into 
the group of low I L l a  and low IL 1(3 producers or high 
I L l a  and high IL 1(3 producers (Fig. 3 B ) .T h e  correlation 
coefficient is R = 0.69. Using 30 ¡ig/ml of P H A  as a 
stimulus, we found no correlation between production of
IL 2  and IL 1(3 (R = - 0 .1 0 )  or IL 2  and T N F  (R = - 0 .2 7 )  
measured in the same PBM C samples.
Medication3^ No Yes
Males 19 4
Females 19 8
Age (years)
Median 27 30
Mean 29.1 30.4
Range 20 -  42 23 -43
a) Cyclooxygenase inhibitors.
3.4 Comparison of in vitro cytokine production with the 
proportion of monocytes in the population of PBMC
For the group of 32 subjects the mean percentage of 
monocytes in the PBM C cultures was 19.7% ( ±  10.5% SD) 
as determ ined morphologically. There  was no correlation 
between the percentage of monocytes in the PBM C 
population and the am ount of LPS-induced IL 1(3 (correla­
tion coefficient /? =  0.08), I L l a  (Æ =  0.15) or T N F 
(R  =  0.07) produced. Correlation of IL 1(3 production and
Table 2. Distribution of cytokine production  for 32 subjects w ithout m edicationa)
Cytokine: IL1(3 IL la  TNF IL2
Stimulus: LPS LPS LPS PHA
0.5 ng/ml 0.5 ng/ml 0.5 ng/ml 30 pig/ml
Mean cytokine 5.6 ng/ml 10.1 ng/ml 2.2 ng/ml 9.4 ng/ml
production
SD ±3.2  ±4.7 ±1 .4  ±6.9
Percentile (10th-90th)b) (1.8-10.5) 3.6-16.1) (0.8-4.0) (3.7-17.6)
a) Calculated for the da ta  illustrated in Fig. 2.
b) Tenth percentile indicates concentra tions bel­
ow which samples from  10% of the subjects 
fall. N inetie th  percentile  indicates concen tra ­
tion below which samples from 90% of the 
subjects fall. D a ta  are not available for I L l a  
production  in 1 and for IL 2  production  in 3 of 
the 32 subjects.
2330 S. Endres, J. G. Cannon, R. Ghorbani et al Eur. J. Immunol. 1989. 19: 2327-2333
(A)
E
O)
C
I-
IL 1 (3 (ng/ml)
(A)
Esterase positive cells [% of PBMC]
(B)
2 0 -
□ □
□
16- □ °
□
E □
?  1 2 - □ 
□ 
□ □ □- --- n □ D□□□
100 
X) 
i □ C
D □ □
1
□ □
4 - □ □
°D
0 n
□
i I i 1 I I
0 2 4 6 8 10  12
IL 1 p (ng/ml)
FigurcS. Covariation of  IL 1 (3, IL l a  and T N F  production. (A) 
Concentra tion  of T N F  vs. concentration of  IL 1 (3 is plotted for 
respective subjects (correlation coefficient R = 0.18). (B) C oncen­
tration o f  IL l a  vs. concentra tion of IL lp  (R = 0.69). PBM C from 
32 subjects were stimulated with 0.5 ng/ml LPS, and total p roduc­
tion of  I L l p .  I L l a  and T N F  was assayed by R IA . Each square 
represents one subject. T he  vertical lines indicate the median 
conentra tion  for IL lp  (5.9 ng/ml); the horizontal lines indicate the 
median concentra tions of T N F  (1.9 ng/ml) and of I L l a  
(10.5 ng/ml). (A) has 31 entries since the sample from one o f  the 
subjects was not assayed for IL l a .
proportion of esterase-positive cells in the PBMC popula­
tion was studied in a group of 7 subjects. In this group 
PBMC were isolated and stimulated on two different days, 
two days apart for each individual.There was no correlation 
(R = 0.09) between the mean esterase-positive cell p ropor­
tion and mean production of IL 1(3, both determ ined as the 
mean of two different days (Fig. 4A ).T h is  lack of correla­
tion is not due to lack of precision in determination of either 
cytokine concentration or esterase-positive cell proportion, 
since both these values are reproducible for a given subject 
on two different days (R = 0.87 for IL lp  data  in Fig. 4B; 
R  =  0.65 for esterase-positive cell proportion, data not in 
figure).
Furtherm ore , we examined w hether  for a given individual 
the day to day variaton of in vitro IL ip  production 
correlated with day-to-day variation in the proportion of 
esterase-positive cells in the PBM C population (intraindi-
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Figure 4. Production of IL1|3 vs. p roportion  of esterase-positive 
cells in the PBM C population. PBM C from seven subjects were 
s t imulated with 5 ng/ml of  LPS on two different days two days 
apart .Total  (associated plus secreted) cytokine was de te rm ined  by 
RIA . (A) Lack of correlation between production o f  IL 1 (3 and 
proportion of  esterase-positive cells for different individuals. 
Production of  IL1(3 (mean of two different days) is plotted vs. 
mean proportion  of  esterase-positive cells. (B) Intraindividual 
reproducibility of  absolute  production of IL lp  de te rm ined  on two 
different days.
vidual correlation). If the absolute concentration of IL lp  is 
corrected for the proportion of esterase-positive cells 
( n g l L i p  per 2.5 X 106 esterase-positive cells), the day- 
to-day reproducibility is reduced (/? =  0.59) when com­
pared to the day-to-day reproducibility of either absolute 
IL lp  concentration (R = 0.87, panel B) or esterase-posi- 
tive cell proportin (R = 0.65). Thus, we found absolute 
production of IL ip  (e.g. per 2.5 x 106 PBMC) to be the 
param eter  that is the most reproducible in a given indivi­
dual.This is probably due to the fact that mononuclear cells 
o ther  than monocytes, e.g. lymphocytes, make IL 1 and 
T N F [13] and affect each o ther 's  ability to synthesize these 
cytokines.
3.5 Effect of cydooxygenase inhibition in vitro
Addition of indomethacin to the cultures increased IL 1 p 
production in the study group without medication by an 
average of 27%. In this cohort of subjects, this increase did 
not reach significance (p =  0.055 by one-tailed paired
Day 1 : IL 13 [ng/ml]
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Figure 5. Correlation of IL 1 [3 production in vitro with and without 
addition of indomethacin .  PBM C from 32 donors  were stimulated 
with 0.5 ng/ml LPS in the presence or  absence of 1 ug/ml 
indomethacin . Total (cell-associated plus secreted) I L l p  was 
de te rm ined  by RIA . Production of IL 1(3 in the presence of 1 ug/ml 
indom ethacin  (y-axis) is plotted vs. production of  IL lp  in the 
absence of  indom ethacin  (x-axis). Each square represents  one 
ind iv idual .The (diagonal) regression line is calculated by the least 
square  m e th o d .T h e  correlation coefficient is R = 0.83. Addition of 
indomethacin  increases LPS-induced IL ip  production by a mean 
of  27% .
Studen t’s /-test). However, increased production of IL 1(3 
by PBMC in the presence of indomethacin did show a high 
degree of correlation (R  =  0.83) when compared the pro­
duction from PBM C cultured without indomethacin 
(Fig. 5). Low production of I L l p  in certain individuals 
could have been due to the effect of high levels of 
cydooxygenase products which suppress production of 
IL ip in vitro at the level of translation [15]. As apparent 
from Fig. 5 and reflected in the high correlation coefficient, 
however, “ low producers” for IL lp  production without the 
addition of indomethacin were also “ low producers” when 
cydooxygenase was inhibited by indomethacin. Thus, the 
observed intersubject variability in cytokine production is 
not due to differences in cydooxygenase products. Rather,
added to culture added to culture
Figure 6. Effect of cydooxygenase inhibition in vivo and in vitro 
on LPS-induced I L l p  production. PBM C from 44 donors  were 
stimulated with 0.5 ng/ml LPS with or without addition o f  1 ,ug/ml 
indom ethac in .T he  bars to the left com pare  IL ip  production in the 
absence of in vitro indomethacin  between the groups without 
(// =  32) o r  with (n =  12) medication (cydooxygenase inhibitors). 
T he  bars to the right com pare  production of IL ip  from the same 
groups when stimulated in the presence of in vitro indomethacin. 
E rro r  bars indicate s tandard  error  of the mean. * D enotes  
significant difference between the two subject groups by non­
paired, one-tailed S tu d en t’s ¿-test.
it appears to reflect the genuine regulation of I L l p  
production at the pretranslational level in individual sub­
jects.
3.6 Effect on cydooxygenase inhibition in vivo
Production of IL ip  was significantly increased in the group 
who had taken a cydooxygenase inhibitor (8.3 ng/ml; 
n =  1 2 ) as compared the the group without medication 
(5.7 ng/ml; n =  32, p  =  0.048 by one-tailed unpaired Stu­
den t’s /-test; Fig. 6). When PBMC from both groups were 
stimulated in the presence of indomethacin, the production 
of IL lp  was increased in the group without medication but 
was statistically unchanged in the group taking cyclooxy- 
genase inhibitors.
4 Discussion
In the present study we measured the total synthesis of 
IL lp ,  IL l a ,T N F  and IL2  by PBMC stimulated in vitro. We  
used this procedure to define the range and distribution 
pattern for the production of these cytokines in a cohort of 
healthy volunteers. We measured total (cell-associated plus 
secreted) cytokine concentrations in order to assess overall 
cytokine synthesis during 24 h, independent of release 
kinetics.This approximates the in vivo condition since both 
IL1 [16] and T N F [17] may be cell associated and exhibit 
biological activity in that compartment. Furtherm ore, we 
showed that the proportion of cell-associated vs. secreted 
cytokine differs for the two forms of IL 1 and T N F and, 
moreover, exhibits wide intraindividual variation. This 
latter finding is an important consideration in performing 
gene linkage studies in health or disease.
We chose to stimulate the entire population of PBMC 
rather than enriched subpopulations. Although most of the 
IL 1 and T N F are produced by monocytes, it has been 
shown thatTcells  [18], B cells [19] and NK cells [13, 20] also 
synthesize IL 1 and TNF. Thus, we believe that for the 
purpose of this study the response of the whole PBMC 
population is biologically more relevant than that of 
enriched subpopulations. M ononuclear cells o ther  than 
monocytes may contribute to IL 1 and T N F production 
through cell contact or through formation of o ther  cyto­
kines, such as IFN-y.We demonstrate  that the proportion of 
monocytes and production of IL lp  do not correlate 
between individuals. For a given individual, correction of 
IL ip  production for the monocyte proportion in the 
population of stimulated PBMC actually reduces the 
reproducibility of this parameter.
During enrichment procedures variability due to differ­
ences in monocyte adherence and recovery may interfere. 
Monocyte adherence can be altered in disease [21] and in 
subjects taking medication with cydooxygenase inhibitory 
activity [22]. Finally, stimulating the whole PBMC popula­
tion allows measurement of cytokines originating p redom ­
inantly from monocytes (IL 1(3, IL l a  and TNF) or lympho­
cytes ( IL 2  and TNF) in the same sample employing the 
same stimulus. This allowed us to examine w hether IL 1 or 
T N F  production correlated with IL 2  production in the 
samples stimulated with PH A .
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We report here that 0.5 ng/ml of LPS stimulated more IL l a  
than IL lp  or T N F  (IL l a  >  IL 1(3 >  TN F).This  is somewhat 
surprising given the fact that transcription of IL 1(3 in PBMC 
exceeds that of IL 1 a  by 20- to 50-fold [23]. Since our results 
are based on measuring immunoreactive I L l a  and I L l p ,  
this discrepancy cannot be explained by inhibitors which 
may confound bioassays. The lower level of IL 1(3 in 
response to Fig. 4A is probably not a reflection of prefer­
ential degradation during incubation and freeze thawing 
since, in another study using a different stimulus (heat- 
killed S. epidermidis) , we found production of I L l p  to 
exceed production of I L l a  [10].
There appears to exist a normal distribution for cytokine 
production in vitro , as judged from the pattern  in Fig. 2 and 
as calculated by the Wilk-Shapiro test. Normal distribution 
of a param eter  is a prerequisite for performing standard 
statistical procedures such as S tudent’s t-test on sample 
groups. Within the normal distribution the production of 
the four cytokines is spread over a wide range,indicating 
high intersubject variability. There appear to be individuals 
with high and with low production of particular cytokines in 
vitro.
We have previously examined the intrasubject reproduci­
bility of in vitro cytokine production [10]. We demonstrated 
that in vitro production of IL lp ,  IL l a  and T N F is a 
reproducible param eter  when assayed in a given individual 
on different occasions, several days apart. Furtherm ore, 
when PBMC from healthy subjects were stimulated in 
different experiments as far as 25 weeks apart, PBMC from 
the majority of individuals produced similar amounts of 
IL ip  when compared between the two time points. Taken 
together with the results of the present study, there appear 
to be a few subjects who produce consisently low or 
consistently high amounts of a particular cytokine within a 
cohort of healthy subjects. This finding supports the 
concept of high and low producers in response to particular 
stimulants and the concept of genetic factors controlling 
cytokine synthesis. There  is a parallel in the mouse model, 
where certain inbred strains, which are resistant to either 
Gram-negative or Gram-positive toxins, produce less IL 1 
and T N F  in response to these toxins. This is an inherited 
trait that appears to be controlled at the level of translation 
ra ther  than transcription [24, 25].
Correlation analysis reveals a high correlation between 
production of IL lp  and IL l a  contrasting a lack of corre­
lation between IL lp  and T N F production within the study 
cohort. This suggests linked gene regulation for IL lp  and 
IL l a ,  and independent gene regulation for IL ip  and TNF. 
There was no correlation between IL 2  production and 
production of either I L l p  or T N F within the study 
cohort.
There is ample evidence that arachidonic acid metabolites 
are endogenous regulators of IL 1 production. Macrophage 
IL 1 production in vitro is suppressed by addition of 
exogenous P G E 2 or P G L  and is augm ented by inhibition of 
the cydooxygenase pathway [26]. In humans, we have 
shown that dietary supplem entation with eicosapentaenoic 
acid results in decreased production of IL lp ,  I L l a  and 
T N F  [27]. P G E 2 appears to reduce expression of IL 1 at the 
post-transcriptional level by inducing elevated levels of 
cyclic A M P [15]. W hen monocytes are stimulated in the
presence of cydooxygenase inhibitors like indomethacin, 
an enhancem ent of IL 1 synthesis via suppressed P G E 2 
production has been observed [15, 16]. In the present study 
we have observed increased production of I L l p  by an 
average of 27% when PBM C were stimulated in the 
presence of 1 (ig/ml of indomethacin. This increase did not 
quite reach significance (p = 0.055). We have previously 
reported increased production of T N F  in the presence of 
indomethacin [1 2 ].
We were able to demonstrate  that the enhancing effect of 
cydooxygenase inhibitors on production of I L i p  also 
functions in vivo. W hen compared to the cohort without 
medication, we found that the mean production of IL ip  in 
vitro by stimulated PBMC was significantly higher (48%) in 
the group taking cydooxygenase inhibitors.
The authors wish to thank Scott F. Orencole and Drs. Laurie C. 
Miller, George A. Koch and Peter J. Lisi fo r  their valuable 
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